Studien

IndikationKurzbezeichnungEudraCT-Nr.PhaseTitelStudie aktiv?
Ja/nein
ALLGMALL-MOLACT1-BLINA Blast Successor Trial 2015-000733-76IIA confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BITE ® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Blast Successor Trial)ja
ALLGMALL-INITIAL-12016-004836-39IIAn open label phase II study to evaluate the efficacy and safety of inotuzumab ozogamicin for induction therapy followed by a conventional chemotherapy based consolidation and maintenance therapy in patients aged 56 years and older with acute lymphoblastic leukemia (ALL)ja
ALLGMALL 08/20132013-003466-13IVTherapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapieja
ALLALL-RegisterohneohneGMALL ALL-Registerja
AMLSORAML2008-004968-40IIA double-blind, placebo-controlled, randomized, multi-center phase-II trial to assess the efficacy of Sorafenib added to standard primary therapy in adult newly diagnosed AML patients ≤ 60 yearsja
AMLShape2019-004536-37IITreatment of MDS / AML patiens with an impending Hematological relapse with Azaci-tidine alone or in combination with PEvonedistat – a randomized phase 2 trial ja
AMLETAL3-ASAP2014-003124-44IIIEvaluation of the impact of remission induction chemotherapy prior to allogeneic stemm cell transplantation in relapsed and poor-response patients with AMLja
AMLETAL-12010-019377-15Randomisierte Studie zur allogenen hämatopoetischen Stammzelltransplantation im Vergleich zur Standardchemotherapie bei Patienten in erster kompletter Remission im Alter von ≤60 Jahren mit AML intermediärem Risiko (Standardrisiko) und passendem Geschwister- oder Fremdspenderja
AMLEORTC No. 13012014-001486-27III10-day decitabine versus conventional chemotherapy ("3+7") followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Groupja
AMLDELTA-12014-003150-13IIA randomized placebo-controlled phase 2 study of Decitabine with or without Eltrombopag in AML patients ≥65 years of ageja
AMLCPKC412A23012006-006852-37IIIA phase III randomized, double blind study of induction (daunorubicin/cytarabine) and con­solidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diag­nosed patients <60 years of age with FLT3 mutated Acute Myeloid Leukemia ja
AMLBLAST2014-002702-21IIA double-blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 Addition to consolidation therapy in AML patientsja
AMLARO-0132017-001600-29IIIPhase III, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crnolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemiaja
AMLAML-Registern/aohneAML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL)ja
AMLAG-221-AML-004 IDHENTIFY2015-000344-42IIIA phase 3, multicenter, open-label, randomized study comparing the efficacy and safety of AG-221 (CC-90007) versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an isocitrate dehydrogenase 2 mutationja
AMLAG120-C-0092016-004907-30IIIA Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapyja
AMLAC220-A-U302 QuANTUM-First2015-004856-24IIIA Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) in Combination with Induction and Consolidation Chemotherapy, and Maintenance Therapy in Patients 18 to 70 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemiaja
AML2DAUNO (DaunoDouble)2013-003191-12IIIRandomized comparison between two dose levels of daunorobicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia ≤ 60 yearsJa
AML / MDSRELA02 RELAZA22010-022388-37IIBehandlung des drohenden hämatologischen Rezidivs von Patienten mit MDS oder AML mit 5-Azacytidin (Vidaza®) (RELAZ002-Studie): Eine prospektive, offene, einarmige, multizentrische Phase II Studieja
AML / MDSPALOMA2018-002430-21IIPrimary comparison of liposomal Anthracycline based treatment versus conventional care strategies before allogeneic cell transplantation in patients with higher risk MDS and oligoblastic AML - the PALOMA studyja
AnämieMOM-M281-0062019-000720-17II/IIIEfficacy and Safety of M281 in Adults with Warm Autoimmune
Hemolytic Anemia: A Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Study with a Long-term Open-label
Extension
ja
AnämieEMAA 93452014-000174-19II/IIIEfficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A. Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopag (Revolade ®, GlaxoSmithKline) with Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin Aja
AnämieCSEG101A23012017-001746-10IIIA phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus Placebo, wth or without Hydroxyurea/Hydroxycabamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crisis (STAND)ja
AnämieC-935788-0572018-004774-97IIIA Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fastamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemiaja
APLNAPOLEON-RegisterohneNational Acute Promyelocytic Leukemia (APL) Observational Study Napoleon-Registry of the German AML-Intergroupja
APLAPOLLO2015-001151-68IIIA randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemiaja
CADPDY16370
BIVV020
2019-001844-221bA multicenter, Phase 1b, open label, nonrandomized, single dose study evaluating the safety, tolerability and activity of BIVV020 in adults with cold agglutinin diseaseja
CADBIVV009-04 Cadenza2017-003539-12IIIA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease without a Recent History of Blood Transfusionja
CADBIVV009-03 Cardinal2017-003538-10A Pivotal, Open-Label, Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease who have a Recent History of Blood Transfusionja
CLLCLL-RT12018-002492-17IIA Prospective, Open-Label, Multicentre Phase-II-Trial To Evaluate The Efficacy And Safety Of Zanubrutinib (BGB-3111), A BTK Inhibitor, Plus Teslelizumab (BGB-A317), A PD-1 Inhibitor, For Treatment Of Patients With Richter Transformation (CLL-RT1-Trial Of The GCLLSG)ja
CLLCLL-Registern/aohneRegistry of the German CLL Study Group: Long term follow-up of patients with CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL and Richter´s transformationja
CLLCLLM12011-004698-98IIIEine multizentrische, randomisierte, doppelblinde, plazebokontrollierte Phase 3 Studie, in der parallel die Wirksamkeit und Sicherzeit von Lenalidomid (Revlimid®) als Erhaltungstherapie bei CLL-Patienten mit einem hohen Risiko eines frühen Progresses nach Erstlinienbehandlungja
CLLCLL2-GIVe2015-004606-41IIA prospective, open-label, multicentre phase-II trial of ibrutinib plus venetoclax plus obinutuzumab in physically fit (CIRS ≤ 6 normal creatinine clearance) and unfit (CIRS > 6 & creatinine clearance ≥ 50ml/min) patients with previously untreated chronic lymphocytic leukemia (CLL) with TP53 deletion (17p-) and/or mutationja
CLLCLL2-BIO2014-000590-39IIA prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ibrutinib and ofatumumab (BIO) followed by ibrutinib and afatumumab maintenance in CLL patientsja
CLLCLL13 "GAIA"2015-004936-36IIIA phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RVE) versus obinutuzumab (GA101) plus venetoclax (GVE) versus obinutuzumab plus ibrutinib plus venetoclax (GIVE) in fit patients with previously untreated chronic lymphocyic leukemia (CLL) without del(17p) or TP53 mutationja
CLLCLL122013-003211-22IIIA placebo-controlled, double-blind, randomized, multicenter phase III trial of Ibrutinib vs. deferred treatment in previously untreated Binet stage A CLL with risk of early disease progressionja
NHLAlternative C2018-004038-13IIA Prospective Multicenter Phase 2 Study of the Chemotherapy-Free. Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with previously Untreated Follicular Lymphoma (FL) and a High Tumor Burdenja
CLLACP-196 D8220C00008
(Astra Zeneca)
ohneIII bA Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemiaja
CMLPONS2016-000618-30IIPhase 2 Clinical Trial with Ponatinib as a Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to prior First Line Tyrosine Kinase Inhibitor Treatmentja
CMLPonderosaIVBeobachtungsstudie mit Patienten mit CML in allen Phasen, die mit Ponatinib (Iclusig ®) in jeglicher Dosierung behandelt werdenja
CMLNAUT CAMN107ADE22T2015-004998-33Multicenter prospective trial after first unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping TKI a 2nd timeja
CMLFascination2018-002256-33IIFrontline Asciminib combination in chronic phase CMLja
CMLENDURE CML-IX2016-001030-94IIRandomisierte Phase II Studie zur Untersuchung der Sicherheit und Effektivität einer Therapie mit pegyliertem Prolin-Interferon alpha 2b (AOP2014) zur Erhaltung einer tiefen molekularen Remission bei Patienten mit chronischer myeloischer Leukämie – eine randomisierte, multizentrische Phase-II-Studie mit anschließender Nachbeobachtungsphase außerhalb der Studieja
CMLDastop-2 MED3_2017012016-004106-34IIPersistance of major molecular remission in chronic myeloid leukemia after a second stop of TKI treatment in patients who failed an initial stop attempt: a multicenter prospective trailja
CMLDasaHIT2015-003502-16IIITreatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative ABL-kinase inhibitors (≥2nd line)ja
CMLCAMN107ADE20 NILO-deep-R2015-000968-34IVA Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years of treatment with nilotinib 300 mg BIDja
HDTargeted BEACOPP2011-005082-21IITargeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphomaja
HDNIVAHL2016-002626-37IINIVAHL - Nivolumab and AVD in early-stage unfavorable classical Hodgkin lymphoma: A GHSG randomized, multicenter phase II trialja
HDHD-R3i Ever-DHAP2010-021086-73I/IIA prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or refractory Hodgkin Lymphomaja
HDHD212014-005130-55IIITreatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADDja
HDHD182007-003187-22ohneTherapieoptimierungsstudie in der Primärtherapie
des fortgeschrittenen Hodgkin Lymphoms:
Therapiestratifizierung mittels FDG-PET
ja
HDHD172007-005920-34IIITherapieoptimierungsstudie in der Primärtherapie des intermediären Hodgkin-Lymphoms: Therapiestratifizierung mittels FDG-PETja
HDHD162007-004474-24ohneTherapieoptimierungsstudie in der Primärtherapie des frühen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PETja
HDGHSG-AFM132014-004036-19IIGHSG-AFM13: An open-label, randomized, multicenter phase II trial with AFM13 in patients with relapsed or refractory Hodgkin Lymphoma (HL).ja
ITPARGX-113-18032019-002100-41IIIA Long-Term, Single-Arm, Open-Label, Multicenter, Phase III Follow-On Trial to Evaluate Safety and Efficacy of Intravenous Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopeniaja
ITPARGX-113-18012019-002100-41IIIA Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopeniaja
MCLTRIANGLE2014-001363-12IIIAutologous Transplantation after a Rituximab/Ibrutinib/Ara-C containing induction in generalized mantle cell lymphoma - a European MCL network studyja
MCLR2 elderly2012-002542-20IIIEfficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphomaja
MCLPCYC-1143-CA2017-000129-12IIIPhase 3 Study of Ibrutnib in Combination with Venetoklax in Subjects with Mantle Cell Lymphomaja
MCLPCI-32765CAN30012012-004225-24IIIbA phase 3b, multicenter, open-label, PCI-32765 (Ibrutinib) long-term extension studyja
MCLINCB 50465-205 CITADEL-2052017-003148-19IIA Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)ja
MMGMMG-HD62014-003079-40IIISafety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Lowdoseja
MMCC-4047-MM-0072014-000268-17IIIA phase 3, multicenter, randomized, open-label study to compare the efficacy and safety of pomalidomide, bortezomib and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myelomaja
MMC16019 "Tourmaline"2013-002076-41IIIPlacebokontrollierte, randomisierte Phase III-Doppelblindstudie zur oralen Erhaltungstherapie mit Ixazomib Citrat (MLN9708) im Anschluss an eine autologe Stammzelltransplantation bei Patienten mit Multiplem Myelomja
MM54767414MMY2065LYNX2018-004185-34IIA Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatmentja
MM GMMG-CONCEPT2016-000432-17IIEine klinische Phase II Studie zur Induktions-, Konsolidierungs- und Erhaltungstherapie mit Isatuximab, Carfilzomib, Lenalidomid und Dexamethason (I-KRd) in der Primärtherapie des Hochrisikomyelomsja
MPNSRA-MMB-3012019-000583-18IIIA Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of
Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic
Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV)
Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who
were Previously Treated with JAK Inhibitor Therapy
ja
MPNSAL-MPN-RegisterohneohneSAL-MPN-Register und Biomaterieldatenbank der Studienallianz Leukämie (SAL)ja
MPNRuxo-BEAT, 12-1812013-002132-25IIBRuxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia - The Ruxo-BEAT Trialja
MPNMPNSG 02-12 POMINC2012-002431-29Ib/IIA Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosisja
MPNMMM 02 study CTC127292014-005210-28IIRuxolitinib versus allogenic stem cell transplantation für patients with myelofibrosis according to donor availability: A prospective phase II (MMM 02study)ja
MPNIMG-7289-CTP-2012019-003659-13IIA Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemiaja
MPNIMG-7289-CTP-1022018-003811-23I/IIA Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients with Myelofibrosisja
MPNCINC424BDE12 PaVe-NISohneohnePaVe - Eine prospektive, nicht-interventionelle Studie zur JAKAVI®-Behandlung von Patienten mit Polycythaemia veraja
MPNBesremi-PASS EUPAS29462ohneIIbA Prospective, Multicentre, Non-interventional,
Observational, Post-authorisation Safety Study of
Ropeginterferon alfa-2b in Polycythaemia Vera Patients
ja
MZoLOLYMP-12017-003149-56IIPhase II, single arm, multicentric, open label, non-randomized: Obinutuzumab in marginal zone lymphomaja
MZoLMarginalzonenlymphom-Registern/aNicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomenja
MZoLINCB 50465-204 CITADEL-2042017-000970-12IIA Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphome With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)ja
NHL agg.SGN35-014 "ECHELON-2"2012-002751-42IIIA randomized, double-blind, placebo-controlled, phase 3 study of CH-P and brentuximab vedotin versus CHOP in the front-line treatment of patients with CD30‑positive mature T-cell lymphomasja
NHL agg.Ro-CHOP2012-001580-68IIIPhase 3 multi-center randomized study to compare efficacy and safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphomaja
NHL agg.PTLD-2 2013-004479-11IIRisk-stratified sequential treatment of post-transplant lymphoproliferative desease with 4 courses of Rituximab SC followed by 4 courses of RituximabSC, 4 courses of Rituximab SC combined with CHOP-21 or 4 courses of Rituximab SC combined with alternating CHOP-21 and DHAOx: The PTLD-2 trialja
NHL agg.KTE-C19-101 ZUMA-12015-005007-86I/IIA Phase 1-2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA1)ja
NHL agg.ImbruVeRCHOP2015-003429-32ohneIbrutinib, Bortezomib s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2ja
NHL agg.IELSG-37IIIA randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)ja
NHL agg.GOAL / ETN-12014-004780-21IIRescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with Pixantrone for the treatment of patients with relapsed Aggressive B-cell Lymphomaja
NHL agg.GO39942 Polarix2017-002023-21IIIA Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphomaja
NHL agg. MB-CART2019.1
M-2018-331
2018-001253-27I/IIA Phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or refractory CD20 and CD19 positive B-NHLja
NHL agg. DSHNHL 2015-1 NIVEAU2016-002272-27ohneImprovement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of CD20+ Diseaseja
NHL ind.ML29941 GAZAI2016-002059-89ohneTherapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaroja
NHL ind.HOVON 110 FL ReBeL Study2011-000097-56I/IIA randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma.ja
NHL ind.ALTERNATIVE2014-005164-15IIA Prospective Multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton´s Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burdenja
NHL ind. GABe 20162016-000755-27IIIFirst line therapy of advanced stage follicular lymphoma in patients not eligible for standard immunochemotherapy. Prospective randomized comparison of single agent GA101 versus GA101 plus bendamustine followed by GA101 in medically non-fit patientsja
NHL ind. BO21223 "Gallium"2010-024132-41IIIA multicenter, Phase III, open-label, randomized study in previously untreated patients with advanced indolent non-hodgkin’s lymphoma comparing GA101 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab maintenance therapy in respondersja
PNHCLNP023X22012017-000888-33ohneAn open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in Patients with paroxysmal nocturnal hemoglobinuria (PNH) with signs of active hemolysisja
PNHBP39144 "Composer"2016-002128-10I/IIAn adaptive phase I/II study to assess safety, efficacy, phamacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH)ja
PNHAPL2-3072019-001106-23IIIAn Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).ja
PNHALXN1210-PNH-2012015-002674-20IIA Phase 2, Open-Label, Multiple Ascending-Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)ja
WaldenströmStiL-Studie NHL 7-2008 "MAINTAIN"2008-005859-16ohneProspektiv randomisierte Studie zur Therapieoptimierung (Primärtherapie) fortgeschrittener progredienter follikulärer und anderer niedrigmaligner sowie Mantelzell Lymphomeja
WaldenströmECWM-12013-000506-37IIIEfficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström´s Macroglobulinemiaja
ZNSMARTA2016-001628-72IIMultizentrische Phase II-Studie zur altersadaptierten Hochdosistherapie gefolgt von autologer Stammzelltransplantation bei fitten älteren Patienten > 65 Jahren mit primär zerebralem Lymphomja
ZNSIELSG 32 < 65 Jahre2009-012432-32IIRandomized phase II trial on primary chemotherapy with high-dose methothrexate and high-dose cytarabine with or without Thiotepa, and with or without Rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immuno competent patients with newly diagnosed primary CNS lymphoma. Prüfplan Nr. 000643ja
ZNSFreiburger ZNS-NHL-Hochdosisstudie2005-000615-99ohneTherapie für Patienten mit primären Non-Hodgkin-Lymphomen des ZNS – Sequentielle Hochdosis-Chemotherapie mit autologer peripherer Blutstammzelltransplantation. Prüfplan Nr. 000465ja
ZNS / NHLIELSG43 MATRix2012-000620-17IIIHigh-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trialja